# Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

> **NCT02572453** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 25 (actual)

## Conditions studied

- Recurrent Anaplastic Large Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Transformed Non-Hodgkin Lymphoma
- Refractory Anaplastic Large Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Refractory Transformed Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Onalespib

## Key facts

- **NCT ID:** NCT02572453
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04-04
- **Primary completion:** 2021-03-18
- **Final completion:** 2021-03-18
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Drug supply issues
- **Last updated:** 2022-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02572453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02572453, "Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02572453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*